Literature DB >> 11207456

Maitake extracts and their therapeutic potential.

M Mayell1.   

Abstract

Maitake (Grifola frondosa) is the Japanese name for an edible fungus with a large fruiting body characterized by overlapping caps. It is a premier culinary as well as medicinal mushroom. Maitake is increasingly being recognized as a potent source of polysaccharide compounds with dramatic health-promoting potential. The most recent development is the MD-fraction, a proprietary maitake extract its Japanese inventors consider to be a notable advance upon the preceding D-fraction. The D-fraction, the MD-fraction, and other extracts, often in combination with whole maitake powder, have shown particular promise as immunomodulating agents, and as an adjunct to cancer and HIV therapy. They may also provide some benefit in the treatment of hyperlipidemia, hypertension, and hepatitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207456

Source DB:  PubMed          Journal:  Altern Med Rev        ISSN: 1089-5159


  21 in total

1.  Macrophage activation by edible mushrooms is due to the collaborative interaction of toll-like receptor agonists and dectin-1b activating beta glucans derived from colonizing microorganisms.

Authors:  Jin Zhang; Heather L Tyler; Mona H Haron; Colin R Jackson; David S Pasco; Nirmal D Pugh
Journal:  Food Funct       Date:  2019-12-11       Impact factor: 5.396

2.  Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling.

Authors:  Jianping Fang; Ying Wang; Xiaofen Lv; Xiaokun Shen; Xinyan Ni; Kan Ding
Journal:  Glycoconj J       Date:  2012-06-29       Impact factor: 2.916

3.  Cold-water extracts of Grifola frondosa and its purified active fraction inhibit hepatocellular carcinoma in vitro and in vivo.

Authors:  Chia-Hung Lin; Ching-Yao Chang; Kuan-Rong Lee; Hui-Ju Lin; Wu-Chou Lin; Ter-Hsin Chen; Lei Wan
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-24

4.  Immunomodulatory beta-glucan from Lentinus edodes activates mitogen-activated protein kinases and nuclear factor-kappaB in murine RAW 264.7 macrophages.

Authors:  Xiaojuan Xu; Chen Pan; Lina Zhang; Hitoshi Ashida
Journal:  J Biol Chem       Date:  2011-07-20       Impact factor: 5.157

5.  Bacterial components are the major contributors to the macrophage stimulating activity exhibited by extracts of common edible mushrooms.

Authors:  Heather L Tyler; Mona H Haron; Nirmal D Pugh; Jin Zhang; Colin R Jackson; David S Pasco
Journal:  Food Funct       Date:  2016-10-12       Impact factor: 5.396

6.  Pharmacological and pharmacokinetic studies with agaricoglycerides, extracted from Grifola frondosa, in animal models of pain and inflammation.

Authors:  Chuncho Han; Bo Cui
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

7.  Grifola frondosa water extract alleviates intestinal inflammation by suppressing TNF-alpha production and its signaling.

Authors:  Jong Suk Lee; Su Young Park; Dinesh Thapa; Mi Kyoung Choi; Ill Min Chung; Young Joon Park; Chul Soon Yong; Han Gon Choi; Jung Ae Kim
Journal:  Exp Mol Med       Date:  2010-02-28       Impact factor: 8.718

8.  Genes related to suppression of malignant phenotype induced by Maitake D-Fraction in breast cancer cells.

Authors:  Eliana Noelia Alonso; Manuela Orozco; Alvaro Eloy Nieto; Gabriela Andrea Balogh
Journal:  J Med Food       Date:  2013-07       Impact factor: 2.786

9.  A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects.

Authors:  Gary Deng; Hong Lin; Andrew Seidman; Monica Fornier; Gabriella D'Andrea; Kathleen Wesa; Simon Yeung; Susanna Cunningham-Rundles; Andrew J Vickers; Barrie Cassileth
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-01       Impact factor: 4.553

10.  Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma.

Authors:  Shakeel Modak; Brian H Kushner; Kim Kramer; Andrew Vickers; Irene Y Cheung; Nai-Kong V Cheung
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.